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Two myxoma virus-rabbit hemorrhagic disease virus (RHDV) recombinant viruses were constructed with the
SG33 strain of myxoma virus to protect rabbits against myxomatosis and rabbit viral hemorrhagic disease.
These recombinant viruses expressed the RHDV capsid protein (VP60). The recombinant protein, which is 60
kDa in size, was antigenic, as revealed by its reaction in immunoprecipitation with antibodies raised against
RHDV. Both recombinant viruses induced high levels of RHDV- and myxoma virus-specific antibodies in
rabbits after immunization. Inoculations by the intradermal route protected animals against virulent RHDV
and myxoma virus challenges.
Two major viral diseases affect European rabbit populations
(Oryctolagus cuniculus) in continental Europe: myxomatosis
and rabbit viral hemorrhagic disease (RVHD). The wild rabbit
population is an important reservoir for both viruses.
The etiological agent of myxomatosis, myxoma virus (MV),
is a large double-stranded DNA virus belonging to the Lepo-
ripoxvirus genus of the Poxviridae family (12). It induces a mild
disease in cottontail rabbits (Sylvilagus spp.) but a systemic and
usually fatal one in European rabbits (11).
Control of the disease is very difficult because of its epide-
miological characteristics. Only vaccination can reduce the
spread of myxomatosis in breeding animals. In France, primary
vaccination is done with Shope fibroma virus, another lepori-
poxvirus, and a cell culture-attenuated strain of MV (SG33) is
used for booster injections (34). Nevertheless, the SG33 strain
may at times show residual pathogenicity for young rabbits (7).
RVHD, a highly contagious disease in wild and domestic
rabbits, was first described in the People’s Republic of China in
1984 (19). RVHD spread throughout Europe between 1987
and 1989 (22). Infected rabbits—adults or young animals older
than two months—usually die within 48 to 72 h of necrotizing
hepatitis and hemorrhagic syndrome (20). The disease is re-
sponsible for high economic losses in rabbitries as well as for
high mortality rates in wild rabbits. The causative agent, the
rabbit hemorrhagic disease virus (RHDV), was characterized
as a member of the Caliciviridae family (25, 28), with a genome
of 7.5-kb single-stranded, positive-sense RNA with two open
reading frames (ORFs). ORF1 extends from nucleotide (nt) 10
to 7042 and encodes a polyprotein that is cleaved into non-
structural proteins and the unique capsid protein VP60 (21,
30). ORF2 overlaps the 3 end of ORF1 by 17 nt and encodes
a 12-kDa protein (21, 28).
Both active immunization with VP60 alone and passive im-
munization with anti-VP60 antibodies were reported to afford
protection against a viral challenge (4, 18, 28). However, be-
cause there is no cell culture system to produce RHDV in
vitro, the source of vaccinal antigen remains the livers of in-
fected animals (1).
The full-length genome of an RHDV isolate collected from
a wild rabbit in France has recently been cloned and sequenced
(30). Laurent et al. (18) showed that a recombinant capsid
protein VP60 expressed in the baculovirus/Sf9 cell expression
system self-assembled into virus-like particles. These virus-like
particles turned out to be highly immunogenic and to induce
good protection against the disease (18). We then showed that
a vaccinia virus-RHDV recombinant virus expressing the VP60
also provided total protection against RVHD when adminis-
tered either intradermally (i.d.) or orally (2).
To simultaneously protect rabbits against myxomatosis and
RVHD, we constructed recombinant MVs based on the atten-
uated SG33 myxoma strain that express the RHDV VP60
protein. We also tried to improve the safety of SG33 virus by
deleting its thymidine kinase (TK) gene (15) or ORFs coding
for the previously identified pathogenesis factors MGF (myx-
oma growth factor) (26, 36) and M11L (14, 26). The abilities of
these recombinant viruses to protect animals against chal-
lenges with virulent RHDV and MV were tested.
MATERIALS AND METHODS
Cells and viruses. MV SG33 and recombinant viruses were propagated in
RK13 cells grown in OptiMEM (Gibco Life Technologies) supplemented with
2% fetal calf serum (FCS [Gibco Life Technologies]).
Amplification and cloning of SG33 virus M11L-MGF and TK genes. Partially
overlapping M11L and MGF ORFs are located approximately 13 kb from the left
terminus of the MV DNA genome (26).
PCR (30 cycles; 1 min at 95C, 1 min at 50C, and 1 min at 72C) was used to
amplify these two ORFs (1,060 bp) with SG33 DNA as the template and primers
5-GTAGGATCCGTAACAAGTGTAAATATA-3 (located upstream of the
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M11L major RNA 5 initiation site) and 5-CCCGGGATGTTTTCGCGATGT
GA-3 (located after the stop codon of MGF).
The TK gene (700 bp) was also obtained by PCR (same parameters) with
SG33 DNA as the template and primers 5-GGTGTTGGATAAGGAAGTT
ACG-3 (located 112 bp upstream from the start codon of the TK gene) and
5-GAGGTCGCTGTCGGAGACG-3 (located 43 bp downstream from the TK
gene putative early transcript termination signal).
The amplification products were ligated into the cloning vector pGEM-T
(Promega), and the M11L-MGF-amplified products were then subcloned into
Bluescript vector (pSK; Stratagene).
Construction of the recombinant transfer vectors pSM1 and pSM2. The
3-terminal 2,133 nt of the RHDV genome, covering the VP60 gene and ORF2
(VP12), which were previously cloned (30) in pSK (Bluescript; Stratagene),
were digested by SacI and SmaI, blunt ended with Klenow polymerase, and
ligated into the transfer vector pSC11 (9) (kindly provided by G. Sutter) at the
SmaI restriction site to produce the pSVV plasmid.
In pSVV, the TK gene of vaccinia virus was interrupted by an insertion of 5.6
kb containing the lacZ gene under the control of the vaccinia virus p11 promoter
and the VP60 and VP12 sequences of RHDV under the control of the vaccinia
virus p7.5 promoter. Correct orientation of the VP60 gene was determined both
by PCR and by restriction enzyme analysis (not shown). First, pSVV was digested
by NotI and then partially digested by PstI. A 5.6-kb restriction fragment, con-
taining the lacZ gene and the VP60 and VP12 genes, was subcloned in pSK to
produce pSM0. The same 5.6-kb digested NotI-KpnI fragment was blunt ended
and ligated into the pGEMT-TK plasmid at the EcoRV restriction site of the TK
ORF to produce pSM2.
A 5.3-kb digested HindIII fragment of pSM0, containing the lacZ and VP60
genes, was ligated into the pSK (M11L-MGF) plasmid at the HindII and BsaBI
restriction sites of the M11L and MGF ORFs to produce pSM1. Correct orien-
tation of the VP60 gene (3 end toward the 3 end of disrupted genes) for the
pSM1 and pSM2 plasmids was confirmed by PCR and restriction enzyme analysis
(data not shown).
Isolation of recombinant viruses. The procedure used to isolate recombinant
MVs was adapted from a method previously used for vaccinia virus (9, 27).
Briefly, 90% confluent RK13 cells, in 60-mm petri dishes, were infected with
SG33 virus at a multiplicity of infection of 0.03 to 0.04 PFU per cell. After 2 h of
adsorption at 37C, the inoculum was removed and the cells were washed twice
with OptiMEM without FCS. For transfection, 10 g of pSM1 or pSM2 plasmid
DNA was first mixed with 40 g of lipofectamine at room temperature for 20
min. The lipofectamine-DNA complex was then added to 3 ml of OptiMEM
serum-free medium and this mix added to the cells. After 5 h and 30 min at 37C,
the medium was supplemented with 3 ml of OptiMEM plus 5% FCS. Forty-eight
hours later, the cells were frozen and thawed three times, sonicated (20 s), and
applied to fresh RK13 cells. Two days later, the medium was removed and fresh
medium containing 1% agar and 2.5% FCS was added. After 48 h, a new medium
containing 1% agar, 1% neutral red, and 330 g of X-Gal (5-bromo-4 chloro-
3-indoyl--galactoside) per ml was added. The following day, blue plaques were
picked and five additional plaque purification cycles were performed under the
same conditions. Recombinant viruses RecA (TK site) and RecB (M11L-MGF
site) were amplified by infection of RK13 cells.
The genome profiles (PstI restriction enzyme digestion) of the two recombi-
nant viruses were determined by pulsed-field gel electrophoresis (PFGE) and
Southern blot analysis, as previously described (29) (data not shown). The DNA
fragments were hybridized to digoxigenin-labeled DNA probes. DNA probes
from the SG33 TK and M11L-MGF genes and an internal fragment (830 nt in
length) of VP60 were prepared as described by the manufacturer (Boehringer
Mannheim) by the random-priming technique.
Immunoprecipitation of the radiolabeled expressed proteins. RK13 cells were
infected with SG33 or recombinant viruses at about 30 PFU per cell. The
infected cells were labeled for 5 h and 30 min in medium containing [35S]me-
thionine (100 Ci/ml). The infected labeled cells were treated with lysis buffer
(10 mM Tris, 2% Triton X-100, 15 mM NaCl, 600 mM KCl, 0.4 mM MgCl2,
protease inhibitors [pH 8]) for 2 h on ice and were centrifuged at 17,000  g for
90 min (4C). The proteins contained in the supernatant of the radiolabeled cell
lysate were immunoprecipitated by using either a monoclonal antibody (MAb)
specific for the VP60 (4E3) (18) or a hyperimmune antiserum and protein
A-Sepharose. Proteins, eluded from protein A-Sepharose, were resolved by
Sodium dodecyl sulfate (SDS)-10% polyacrylamide gel electrophoresis and then
visualized by autoradiography.
Immunization of rabbits with SG33, RecA, and RecB viruses and challenges
with MV and RHDV. Male New Zealand White rabbits (O. cuniculus) (4 to 5
weeks old) were obtained from a local supplier. The rabbits were observed for 3
days to confirm that they were healthy and were then injected once i.d. on the
external part of the ear with a 0.1-ml dose of virus (5  103 PFU) in minimum
essential medium. The rabbits were monitored daily for 2 weeks. The serological
responses against MV and RHDV VP60 were evaluated by use of enzyme-linked
immunosorbent assays (ELISA) (recombinant-purified VP60 or semipurified
MV as antigens) 5, 10, 20, 30, and 44 days after immunization. Briefly, ELISA
plate wells (Falcon probind; Becton Dickinson) were coated with 1 g of recom-
binant baculovirus-purified VP60 or 1 g of semipurified MV. Binding of the
RHDV or MV antibodies was visualized by incubation with goat anti-rabbit
immunoglobulin G serum conjugated to alkaline phosphatase (Sigma). The A405
of each sample was measured 15 min after the addition of substrate solution
(p-nitrophenyl-phosphate in 10% diethanolamine [pH 9.8]) (Sigma). Serological
responses against MV were also evaluated by use of a serum neutralization test
30 and 44 days after immunization. Serum samples were diluted in 96-well
microtiter plates, and an equal volume (50 l containing 750 PFU) of MV (T1
strain) was added to each well. The plates were incubated for 1 h at 37C and 1 h
at 4C. RK13 cells (104 cells in 50 l) were then added to each well, and the
plates were incubated at 37C for 3 days in a CO2 incubator. The plates were read
by examining the unfixed and unstained cell monolayers under an inverted-phase
light microscope.
Rabbits were challenged i.d. on day 44 with virulent MV strain T1 (5  103
PFU) and were then monitored daily for symptoms of myxomatosis. One month
later (75 days after the vaccination), anti-MV antibodies were measured by
ELISA.
To determine whether the recombinant MVs which expressed VP60 could
induce a protective immune response against RHDV, 36 5-week-old New Zea-
land White rabbits were injected i.d. with viruses (5  103 PFU in minimum
essential medium) and 18 others were injected subcutaneously (s.c.) with inac-
tivated classical vaccine in a protected rabbitry at the Centre National d’Etudes
Ve´te´rinaires et Alimentaires (CNEVA) laboratory of Ploufragan, France. One
group of rabbits was then challenged intramuscularly with 1,000 50% lethal doses
of RHDV 5 days after immunization, and a second group was challenged 15 days
after immunization. The rabbits were clinically examinated daily for 7 days after
the challenge. One month later (35 and 45 days, respectively, after the vaccina-
tion), anti-VP60 antibodies were measured by ELISA.
RESULTS
Construction of the RecA and RecB recombinant viruses.
Homologous recombination occurred between the sequences
flanking the foreign gene of both the pSM1 and pSM2 inser-
tion vectors and the corresponding sequences of the infecting
MV (SG33 strain) genome so that two recombinant genomes
containing the foreign DNA were formed.
In the first recombinant MV-RHDV, RecA virus, the TK
gene of the SG33 strain was interrupted by an insertion of 5.6
kb containing the lacZ gene under the control of the vaccinia
virus p11 promoter and the VP60 and VP12 sequences of
RHDV under the control of the vaccinia virus p7.5 promoter.
In the RecB virus, 356 nt were deleted at the 3 end of the
M11L gene and the 5 end of the overlapping MGF gene of the
SG33 strain and were replaced by lacZ and VP60 (without
VP12) sequences (Fig. 1). To confirm the positions of the
foreign DNA inserts within the recombinant viruses genomes,
DNA from infected cells was digested with PstI restriction
endonuclease and analyzed by PFGE and Southern blotting.
The results of the hybridization experiments were analyzed
with respect to the genome structure of MV (Lausanne strain)
described by Russell and Robbins (33), and to the restriction
map of the SG33 strain. This attenuated strain has a deletion
at the right end of the DNA and lacks a fragment of approx-
imately 13 kb (5) compared with the DNA of the Lausanne
strain. The hybridization reactions with the SG33 and VP60
probes confirmed that the inserts were present in a unique
target site in each recombinant virus genome (data not shown).
Expression of VP60 in cells infected by recombinant viruses.
Immunoprecipitation experiments with [35S]methionine-la-
beled lysates of RK13 cells infected with SG33 or recombinant
viruses showed that the proteins expressed in the RecA and
RecB viruses exhibited some characteristics of the authentic
VP60 protein of RHDV. The 4E3 MAb and the specific anti-
serum chosen had previously been used for Western blot (im-
munoblot) analysis with purified RHDV and recombinant bac-
ulovirus VP60 protein (18).
Both MAb and specific antiserum immunoprecipitated a
protein with an apparent molecular mass of 60 kDa (Fig. 2A
and B, lanes b), corresponding to the monomeric form of the
VP60 capsid protein, in agreement with published values (18,
21, 25, 28, 31). A minor band migrating close to the recombi-
nant VP60 was also immunoprecipitated by the polyclonal and
MAbs.
Immune responses and protection induced by recombinant
viruses. After i.d. administration of both recombinant viruses
or the SG33 strain, only a localized primary tumor on the
external part of the ears of the rabbits could be observed. All
induced tumors were similar in terms of size and time frame.
We used this observation to confirm the safety of these viruses
for young rabbits.
To determine whether the VP60 expressed in the RecA and
RecB recombinant MVs was immunogenic for young rabbits,
serial serum samples were monitored for the presence of anti-
VP60 antibodies by ELISA. At the same time, anti-MV anti-
bodies were detected by ELISA and by a neutralization test. A
specific response was observed with both recombinant viruses
when the anti-MV response was tested (Fig. 3 and 4), although
this was lower than the response observed with the SG33
strain. The differences noted between the anti-MV antibody
titers induced by the RecA and RecB viruses were not signif-
icant (P  0.43 by the Mann-Whitney test at day 44).
Anti-VP60 antibodies were detected as early as 5 days pos-
tadministration of the recombinant viruses (titers ranging from
50 to 100). Both groups progressively developed high anti-
VP60 antibody titers, while animals vaccinated with the SG33
strain of MV and the nonvaccinated rabbits remained seroneg-
ative for RHDV (Fig. 5). The RecB virus induced a better
anti-VP60 antibody response than the RecA virus, and this
time the differences were highly significant (P  0.0004 by the
Mann-Whitney test at day 44).
To see whether previously vaccinated rabbits could with-
stand a virulent infection by MV, the animals were challenged
44 days postvaccination with the T1 strain of MV. The propor-
tions of rabbits that survived infection were equivalent in all
three groups, and some of these rabbits showed clinical signs of
myxomatosis without fatality (Table 1). Thus, the recombinant
MV-RHDVs, like the SG33 strain of MV, virus, induced a par-
FIG. 2. Expression of VP60 in MV-RHDV recombinant virus-infected cells;
autoradiographs of SDS-polyacrylamide gels showing 35S-labeled, immunoprecip-
itated VP60 from infected RK13 cells. (A) a, b, and c, SG33-infected cells, RecA-
infected cells, and noninfected cells, respectively; (B) a, b, and c, SG33-infected
cells, RecB-infected cells, and noninfected cells, respectively. Group 1, anti-VP60
MAb; group 2, RHDV antiserum. M, molecular mass markers (in kilodaltons).
FIG. 1. Construction of MV insertion vectors (see Materials and Methods for details). TKL, left part of the vaccinia virus TK gene; TKR, right part of the VV TK
gene; TKmL, left part of the MV (SG33 strain) TK gene; TKmR, right part of the MV (SG33 strain) TK gene. M11L and MGF are genes of the SG33 strain. The
pSM 1 and pSM 2 insertion vectors were used to obtain RecB and RecA recombinant viruses, respectively.
tially protective antimyxomatosis primary immune response.
The postchallenge ELISA titers to MV of rabbits vaccinat-
ed with RecA or RecB virus were very similar, ranging from
80,000 to 300,000.
To investigate the protection induced by the recombinant
VP60 protein, six other groups of young rabbits were vacci-
nated with either RecA virus or RecB virus or a commercially
available inactivated anti-RVHD vaccine at the CNEVA Pl-
oufragan laboratory 5 or 15 days before a challenge with 1,000
50% lethal doses of RHDV. Nonvaccinated animals (control
groups) were also challenged at the same time.
All vaccinated rabbits survived, regardless of the day of
challenge, without clinical signs of disease (Table 2). The rab-
bits challenged 5 days after vaccination with one of the two
recombinant viruses had anti-VP60 antibody titers ranging
from 50 to 100 on the day of challenge. Titers of the other
groups of vaccinated rabbits ranged from 500 to 2,000 on the
day of challenge (15 days postvaccination).
No RHDV could be detected by ELISA in the livers col-
lected from vaccinated animals which were sacrificed 30 days
after challenge. In contrast, all animals in the control groups
died between 48 and 72 h after challenge and had anti-VP60
antibody titers less than the detection limit of the test. RHDV
could be detected in all liver homogenates from these animals
(data not shown).
The postchallenge anti-VP60 antibody titers of rabbits vac-
cinated with RecA or RecB virus were in the ranges 20,000 to
300,000 and 40,000 to 300,000, respectively.
DISCUSSION
RVHD is a new acute disease of domestic and wild rabbits
that has been present in Europe since 1987 (22). The causative
agent (RHDV) is a member of the Caliciviridae family, and a
major structural protein, the capsid protein VP60, has been
identified. The recombinant VP60 protein produced either in
Escherichia coli (4) or in the baculovirus/Sf9 expression system
(18) or by a vaccinia virus-RHDV recombinant virus (2) in-
duces protective immunity.
The use of poxviruses such as the vaccinia virus as viral
vectors for foreign genes for purposes of vaccination was de-
scribed more than 10 years ago (17). These expression systems
have proven their efficacy against many diseases (10, 13, 16, 23,
35). The vaccinia virus-rabies virus recombinant virus, the
Copenhagen strain of vaccinia virus expressing the rabies virus
G glycoprotein (17, 37), for example, has been used success-
fully for routine vaccination against rabies in the wild (oral
vaccination of foxes in France and Belgium) (3, 6).
Moreover, some poxviruses used as viral vectors have an
advantage over the vaccinia virus-based recombinant vaccines
in that they also protect against vector-induced diseases. For
example, recombinant capripoxvirus can protect cattle against
lumpy skin disease (32) and recombinant fowlpoxvirus can
FIG. 3. Serum anti-MV antibody responses (ELISA) in rabbits immunized
i.d. with MV-RHDV recombinant viruses (RecA or RecB) or SG33 virus. The
serological responses were evaluated before challenge and 5, 10, 20, 30, and 44
days after immunization. Antibody titers are reported as reciprocal geometric
mean titers plus standard errors of the means (n  12, 15, 22, and 12, respec-
tively, for the RecA group, RecB group, SG33 group, and control group). The
control group contained nonvaccinated animals.
FIG. 4. MV-neutralizing antibody titers in rabbits after i.d. vaccination with
MV-RHDV recombinant viruses (RecA or RecB) or SG33 virus. Serological
responses were evaluated before challenge and 30 and 44 days after immuniza-
tion. Antibodies titers are reported as reciprocal geometric mean titers plus
standard errors of the means (n  12, 15, 22, and 12 for the RecA group, RecB
group, SG33 group, and control group, respectively). The control group con-
tained nonvaccinated animals.
FIG. 5. Serum anti-VP60 antibody response (ELISA) in rabbits vaccinated
i.d. with recombinant MVs (RecA or RecB) that express RHDV VP60. Antibody
titers are reported as reciprocal geometric mean titers plus standard errors of the
means (n  12, 15, 22, and 12 for RecA, RecB, the SG33 group, and the control
group, respectively). The control group contained nonvaccinated animals. The
serological responses were evaluated 5, 10, 20, 30, and 44 days after immuniza-
tion. None of the rabbits in these groups were challenged with RHDV.
TABLE 1. Protection against MV challenge of rabbits vaccinated with
SG33 or MV-RHDV recombinant viruses (RecA or RecB virus)a
Vaccine
No. of rabbits affected/n
Localized
primary
tumor
Primary and
secondary
tumors
Primary and
secondary
tumors with
debilitation
Mortality
RecA 12/12 6/12 4/12 1/12
RecB 15/15 14/15 7/15 3/15
SG33 22/22 16/22 9/22 3/22
Nonvaccinated 12/12 12/12 12/12 12/12
a Rabbits were challenged i.d. with 5  103 PFU of MV strain T1 44 days
postvaccination. Clinical signs from a localized primary tumor to fatality were
classified. Some of the rabbits that developed generalized symptoms died of
myxomatosis.
protect chickens against challenge with virulent fowlpoxvirus
(24).
Myxomatosis is still a major viral disease of both wild and
domestic rabbits. The causative agent belongs to the Lepori-
poxvirus genus of the Poxviridae family and shares the charac-
teristics required to construct recombinant vaccines. There-
fore, we tried to produce a bivalent vaccine by means of a new
type of recombinant virus so that rabbits could be vaccinated
simultaneously against these two diseases. Two recombinant
MVs expressing RHDV VP60 were constructed. We used the
SG33 MV strain, an attenuated French strain, and attempted
to attenuate its residual pathogenicity for young rabbits by
inactivating either TK (15) or M11L (13) and MGF (36) genes
which encode pathogenesis factors. It has previously been re-
ported that deletions in the M11L and MGF genes dramati-
cally decrease the virulence of wild-type MV (26) and that
inactivation of the vaccinia virus TK gene attenuates pathoge-
nicity in mice (8).
The foreign VP60 in both recombinant viruses was ex-
pressed to a high level, but we also observed a minor band
migrating close to the recombinant VP60. A similar result has
been described for the VP60 of RHDV expressed in the bac-
ulovirus system (18) or by a vaccinia virus-RHDV recombinant
virus (2). However, in contrast to previous reports (18, 21, 31),
we did not detect any proteins migrating with molecular
masses of 30 to 40 kDa. As in recombinant baculovirus (18)
and vaccinia virus-RHDV-infected cells (2), no detectable ex-
pression of the low-molecular-mass protein corresponding to
ORF2 (VP12) could be observed in recombinant RecA virus-
infected cells. No recombinant VP60 could be detected in the
supernatant of infected RK13 cells, in contrast to that observed
in the baculovirus system (18).
One i.d. injection of both MV-RHDV recombinant viruses
was able to protect young rabbits against a virulent RHDV
challenge as efficiently as the commercial vaccines (1) under
the conditions used for vaccine controls in France. On the
whole, the protective immunity against RHDV was rapidly
established, since all of the rabbits vaccinated 5 or 15 days
before challenge were protected. Similar results had been re-
ported previously with inactivated RHDV (1), virus-like par-
ticle (18), VP60 expressed in E. coli (4), or vaccinia virus-
RHDV recombinant virus (2). It is likely that the humoral
response plays a key role in protection against the disease (28)
and that the protective immunity is efficient as soon as anti-
bodies against VP60 can be detected in animal sera (4, 18, 28).
As was observed with the VP60 expressed in the baculovirus/
Sf9 expression system (18) or with a vaccinia virus-RHDV
recombinant virus (2), we found that anti-VP60 antibodies
could be detected as early as 5 days after vaccination and
correlated with resistance to challenge. However, nonspecific
host responses to the live recombinant viruses cannot be ruled
out as effectors of protection in such an early result. On the
contrary, it seems likely that anti-VP60 antibodies might be
fully responsible for the protection of animals that were chal-
lenged 15 days after vaccination. At that time, antibodies had
already risen to moderate to high levels, and previous results
obtained with i.d. inoculation of vaccinia virus 15 days before
RHDV challenge showed no induced protection of rabbits
against RVHD, suggesting that nonspecific responses did not
intervene under these conditions (2). Although rabbits vacci-
nated with RecA or RecB virus were completely protected
against RVHD after the challenge without any clinical sign or
traces of RHDV, a rapid and more-than-10-fold increase in
anti-VP60 antibody ELISA titers was observed. This might
indicate an anamnestic response to RVHD due to challenge
exposure, as well as a good priming effect by the recombinant
VP60 protein.
The differences observed in antibody responses to the re-
combinant VP60 protein in rabbits that received RecA or
RecB have not been explained to date. Whether the two re-
combinant MVs allowed the same antigen presentation of the
foreign gene product remains to be investigated.
We vaccinated seronegative animals at weaning to check
whether such recombinant viruses could be used early in the
rabbit breeding schedule. Under industrial and traditional breed-
ing conditions, maternal RHDV-specific antibodies may block
the effect of an inactivated vaccine administrated at weaning.
The use of an attenuated recombinant virus may help to re-
solve this kind of problem, and specific data should be gath-
ered by testing the recombinant viruses in young rabbits born
from vaccinated does.
A single i.d. injection of a classical dose of either MV-
RHDV recombinant virus gave the same level of partial pro-
tection against myxomatosis as the SG33 virus strain. Thus, the
immunogenicity of MV as a live vaccine was not significantly
impaired by the insertion of a foreign gene into the TK or
M11L-MGF genes of the SG33 virus strain. We did not ob-
serve any signs of residual pathogenicity for young rabbits after
administration of both recombinant viruses in our experiments,
but this result needs to be confirmed under breeding condi-
tions. The partial protection against myxomatosis induced by
both RecA and RecB viruses and the very high increase in
ELISA titers to MV may indicate replication of challenge T1
MV, a sign of nonsterilizing immunity. This result is not sur-
prising, since a single SG33 administration is known to be
insufficient to establish complete protective immunity against
myxomatosis in rabbit.
Early and efficient protection against RVHD and myxo-
matosis may be obtained in young domestic rabbits by i.d.
administration of MV-RHDV recombinant viruses. Such MV-
RHDV recombinant vaccines have several advantages over the
vaccinia virus-based RVHD recombinant vaccine. First, they
protect rabbits against both RVHD and myxomatosis. Second,
the geographical distributions of RHDV and MV are very
similar, so that the use of recombinant vaccines based on MV
will not entail the introduction of viruses that do not already
exist in a particular area. Third, leporipoxviruses, unlike vac-
cinia virus, are very restricted in their host range and are not
pathogenic for human beings. The wide host range of vaccinia
virus has in fact been suggested as a possible cause of prob-
lems, e.g., transmission from target animals to nontarget spe-
cies with the possible associated problem of recombination
with other poxviruses. The choice of a vector with a small host
range, such as MV, may further limit spread of the vector, thus
TABLE 2. Protection against RVHD of rabbits vaccinated s.c. with
inactivated anti-RVHD vaccine or i.d. with MV-RHDV
recombinant viruses (RecA or RecB virus)a
Vaccine
Inocu-
lation
route
Dose
No. of dead
animals/no.
of animals
challenged
at day 5
No. of dead
animals/no.
of animals
challenged
at day 15
RecA i.d. 5 103 PFU 0/8 0/9
RecB i.d. 5  103 PFU 0/9 0/9
Classical vaccine s.c. 1 ml 0/9 0/9
Nonvaccinated 5/5 5/5
a Rabbits were challenged intramuscularly 5 or 15 days postvaccination with
1,000 50% lethal doses of RHDV.
reducing the chance of an exchange of genes with wild-type
pathogens.
We now need to control the efficiency of the oral route so as
to explore the possibility of wild rabbit vaccination. MV-based
recombinant vaccines seem to be good candidates for use in
the control of RVHD in Europe.
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